Date | Insider | Price | Amount |
---|---|---|---|
9-10-2020 Insider Buy |
Wassim Fares Chief Medical Officer |
$10.18 CAGR » |
$40,708.00 4,000 shares |
11-25-2019 Insider Buy |
Theodore T. Wang Director and >10% Owner |
$0.38 CAGR » |
$3,241.16 8,443 shares |
6-12-2019 Insider Buy |
Theodore T. Wang Director and >10% Owner |
$0.64 CAGR » |
$31,905.00 50,000 shares |
5-22-2019 Insider Buy |
Theodore T. Wang Director and >10% Owner |
$0.60 CAGR » |
$16,533.00 27,500 shares |
5-21-2019 Insider Buy |
Fabian Tenenbaum Chief Executive Officer |
$0.59 CAGR » |
$2,975.00 5,000 shares |
5-21-2019 Insider Buy |
Jonathan M. Peacock Director |
$0.61 CAGR » |
$12,198.00 20,000 shares |
5-21-2019 Insider Buy |
Theodore T. Wang Director and >10% Owner |
$0.61 CAGR » |
$26,370.50 43,280 shares |
1-23-2019 Insider Buy |
Associates L. P. Venrock IV >10% Owner |
$0.70 CAGR » |
$99,999.90 142,857 shares |
1-23-2019 Insider Buy |
Associates L. P. Venrock IV >10% Owner |
$0.70 CAGR » |
$99,999.90 142,857 shares |
1-25-2019 Insider Buy |
Naseem Amin Director |
$0.70 CAGR » |
$400,000.30 571,429 shares |
9-12-2018 Insider Buy |
Associates L. P. Venrock IV >10% Owner |
$1.18 CAGR » |
$558,392.50 475,000 shares |
9-12-2018 Insider Buy |
Associates L. P. Venrock IV >10% Owner |
$1.18 CAGR » |
$558,392.50 475,000 shares |
9-7-2018 Insider Buy |
Associates L. P. Venrock IV >10% Owner |
$0.86 CAGR » |
$138,162.00 160,000 shares |
9-7-2018 Insider Buy |
Associates L. P. Venrock IV >10% Owner |
$0.86 CAGR » |
$138,162.00 160,000 shares |
8-16-2018 Insider Buy |
Associates L. P. Venrock IV >10% Owner |
$0.65 CAGR » |
$342,879.06 529,370 shares |
8-16-2018 Insider Buy |
Associates L. P. Venrock IV >10% Owner |
$0.65 CAGR » |
$342,879.06 529,370 shares |
12-9-2016 Insider Buy |
Jens Luehring Director and >10% Owner |
$0.56 CAGR » |
$11,200.00 20,000 shares |
5-17-2016 Insider Buy |
Jonathan M. Peacock President and CEO |
$1.37 CAGR » |
$6,841.50 5,000 shares |
12-16-2015 Insider Buy |
Jonathan M. Peacock President and CEO |
$2.75 CAGR » |
$55,735.68 20,300 shares |
8-19-2015 Insider Buy |
Jonathan M. Peacock President and CEO |
$5.48 CAGR » |
$27,377.00 5,000 shares |
5-20-2015 Insider Buy |
Jonathan M. Peacock President and CEO |
$8.69 CAGR » |
$48,323.07 5,560 shares |
5-20-2015 Insider Buy |
Martin Meglasson Chief Scientific Officer |
$8.40 CAGR » |
$5,980.80 712 shares |
2-19-2015 Insider Buy |
Daniel Tasse Director |
$12.00 CAGR » |
$300,000.00 25,000 shares |
2-19-2015 Insider Buy |
Jens Luehring Director and >10% Owner |
$12.00 CAGR » |
$4,306,992.00 358,916 shares |
2-19-2015 Insider Buy |
Linde North America, Inc. >10% Owner |
$12.00 CAGR » |
$4,306,992.00 358,916 shares |
2-19-2015 Insider Buy |
Matthew S. Holt Director and >10% Owner |
$12.00 CAGR » |
$12,841,992.00 1,070,166 shares |
2-19-2015 Insider Buy |
Adam Weinstein Director and >10% Owner |
$12.00 CAGR » |
$12,841,992.00 1,070,166 shares |
2-19-2015 Insider Buy |
New Mountain Investments II, LLC >10% Owner |
$12.00 CAGR » |
$12,841,992.00 1,070,166 shares |
2-19-2015 Insider Buy |
Robert Nelsen Director and >10% Owner |
$12.00 CAGR » |
$2,551,992.00 212,666 shares |
2-19-2015 Insider Buy |
Venture Fund VI LP Arch >10% Owner |
$12.00 CAGR » |
$2,551,992.00 212,666 shares |
2-19-2015 Insider Buy |
Jonathan M. Peacock President and CEO |
$12.00 CAGR » |
$249,600.00 20,800 shares |
2-19-2015 Insider Buy |
Manesh Naidu Chief Business Officer |
$12.00 CAGR » |
$18,000.00 1,500 shares |
2-19-2015 Insider Buy |
Martin Meglasson Chief Scientific Officer |
$12.00 CAGR » |
$144,000.00 12,000 shares |
2-19-2015 Insider Buy |
Reinilde Heyrman Chief Clinical Dev. Officer |
$12.00 CAGR » |
$18,000.00 1,500 shares |
Also See: Institutional Holders of BLPH
Also See: SEC filings
Growth of $10,000.00 Without Dividends Reinvested |
||
Start date: | 09/11/2020 | |
End date: | 10/19/2023 | |
Start price/share: | $9.86 | |
End price/share: | $0.07 | |
Dividends collected/share: | $0.00 | |
Total return: | -99.29% | |
Average Annual Total Return: | -79.69% | |
Starting investment: | $10,000.00 | |
Ending investment: | $70.97 | |
Years: | 3.10 |
Bellerophon Therapeutics Insider Buying
This Holdings Channel page has presented insider buying activity, covering Directors, officers (such as CEO, CFO, COO, etc.), and >10% owners (who are required to file form 4's with the SEC). Important institutional owners may not fall under these categories, but instead file their holdings quarterly on the latest form 13F filings. While recent Bellerophon Therapeutics insider buying activity is included, there may also be stock sales over this same period (Also See: SEC filings for sales and other details).
Also See: Funds Holding BLPH
Free BLPH Email Alerts: Get Dividend Alerts Get SEC Filing Alerts |
Other companies seeing insider buying close in time to when the Bellerophon Therapeutics Insider Buying occurred are:
Oaktree Strategic Income Insider Buying |